Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)

Breast Cancer Research and Treatment

Volumn 152, Issue 1, 2015, Pages 77-85

  Park, Yeon Hee ^a   Jung, Kyung Hae ^b   Im, Seock Ah ^c   Sohn, Joo Hyuk ^d   Ro, Jungsil ^e   Ahn, Jin Hee ^b   Kim, Sung Bae ^b   Nam, Byung Ho ^e   Oh, Do Youn ^c   Han, Sae Won ^c   Lee, Soohyeon ^d   Park, In Hae ^e   Lee, Keun Seok ^e   Kim, Jee Hyun ^f   Kang, Seok Yun ^g   Lee, Moon Hee ^h   Park, Hee Sook ⁱ   Woo, Sook Young ^a   Jung, Sin Ho ^a   Ahn, Jin Seok ^a   Im, Young Hyuck ^a   more..

^a Sungkyunkwan University School of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e National Cancer Center   (South Korea)

^f Seoul National University Bundang Hospital   (South Korea)

^g Ajou University School of Medicine   (South Korea)

^h Inha University School of Medicine   (South Korea)

ⁱ Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Breast cancer; Chemotherapy; Gemcitabine; Paclitaxel; Quality of life

Indexed keywords

GEMCITABINE; PACLITAXEL; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ADULT; ARTICLE; BREAST CANCER; CANCER CONTROL; CANCER PATIENT; CLINICAL OBSERVATION; CONTROLLED STUDY; DRUG EFFICACY; EORTC QLQ BREAST CANCER MODULE 23; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE C30; FEMALE; HUMAN; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CLINICAL TRIAL; METASTASIS; PATHOLOGY; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; NEOPLASM METASTASIS; PACLITAXEL; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84991442432     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3450-z     Document Type: Article

References (20)

1. Goodwin PJ, Black JT, Bordeleau LJ, Ganz PA (2003) Health-related quality-of-life measurement in randomized clinical trials in breast cancer–taking stock. J Natl Cancer Inst 95:263–281
2. Lemieux J, Goodwin PJ, Bordeleau LJ, Lauzier S, Theberge V (2011) Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001–2009). J Natl Cancer Inst 103:178–231. doi:10.1093/jnci/djq508
3. Kramer JA, Curran D, Piccart M, de Haes JC, Bruning P, Klijn J, Van Hoorebeeck I, Paridaens R (2000) Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 36:1498–1506
4. Coates A, Gebski V, Signorini D, Murray P, McNeil D, Byrne M, Forbes JF (1992) Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. J Clin Oncol 10:1833–1838
5. Efficace F, Biganzoli L, Piccart M, Coens C, Van Steen K, Cufer T, Coleman RE, Calvert HA, Gamucci T, Twelves C, Fargeot P, Bottomley A (2004) Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer 40:1021–1030. doi:10.1016/j.ejca.2004.01.014
6. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L (2004) Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 22:2061–2068. doi:10.1200/jco.2004.08.048
7. Quinten C, Coens C, Mauer M, Comte S, Sprangers MA, Cleeland C, Osoba D, Bjordal K, Bottomley A (2009) Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 10:865–871. doi:10.1016/s1470-2045(09)70200-1
8. Lee CK, Stockler MR, Coates AS, Gebski V, Lord SJ, Simes RJ (2010) Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. Br J Cancer 102:1341–1347. doi:10.1038/sj.bjc.6605649
9. Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, Williams A, de Haes HC, Hopwood P, Cull A, Aaronson NK (1996) The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 14:2756–2768
10. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376
11. Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144
12. Ejlertsen B, Pfeiffer P, Pedersen D, Mouridsen HT, Rose C, Overgaard M, Sandberg E, Kristensen B (1993) Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 29:527–531
13. Muss HB, Case LD, Richards F 2nd, White DR, Cooper MR, Cruz JM, Powell BL, Spurr CL, Capizzi RL (1991) Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 325:1342–1348. doi:10.1056/nejm199111073251904
14. Falkson G, Gelman RS, Pandya KJ, Osborne CK, Tormey D, Cummings FJ, Sledge GW, Abeloff MD (1998) Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 16:1669–1676
15. Coates A, Gebski V, Bishop JF, Jeal PN, Woods RL, Snyder R, Tattersall MH, Byrne M, Harvey V, Gill G (1987) Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 317:1490–1495. doi:10.1056/nejm198712103172402
16. Harris AL, Cantwell BM, Carmichael J, Wilson R, Farndon J, Dawes P, Ghani S, Evans RG (1990) Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet 335:186–190
17. Nooij MA, de Haes JC, Beex LV, Wildiers J, Klijn J, Becquart D, Jassem J, Engelsman E, Duchateau L (2003) Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. Clinical outcomes and oncologists’ preferences. Eur J Cancer 39:614–621
18. Gennari A, Amadori D, De Lena M, Nanni O, Bruzzi P, Lorusso V, Manzione L, Conte PF (2006) Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol 24:3912–3918. doi:10.1200/jco.2006.06.1812
19. Gennari A, Stockler M, Puntoni M, Sormani M, Nanni O, Amadori D, Wilcken N, D’Amico M, DeCensi A, Bruzzi P (2011) Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 29:2144–2149. doi:10.1200/jco.2010.31.5374
20. Alba E, Ruiz-Borrego M, Margeli M, Rodriguez-Lescure A, Sanchez-Rovira P, Ruiz A, Mel-Lorenzo JR, Ramos-Vazquez M, Ribelles N, Calvo E, Casado A, Marquez A, Vicente D, Garcia-Saenz JA, Martin M (2010) Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res Treat 122:169–176. doi:10.1007/s10549-010-0860-9